Homology modeling of the dopamine D2 receptor and its testing by docking of agonists and tricyclic antagonists.

We present the first model of dopamine D2 receptor transmembrane helices constructed directly from the bacteriorhodopsin (bR) coordinates derived from two-dimensional electron diffraction experiments. We have tested this model by its ability to accommodate rigid agonist and semirigid antagonist molecules which were docked into the putative binding pocket with stabilizing interactions. The model is consistent with structure-activity relationships of agonists and antagonists that interact with the receptor. It also illuminates data on a Na+ site for regulation of receptor function. The plausibility of the model is increased by its consistency with many mutagenesis studies on G protein-coupled receptors. Further, this model provides a basis to suggest testable molecular mechanisms for changes in the D2 conformational states for high- and low-affinity binding and signal transduction. Changes in the conformational state of the receptor are hypothesized to be due partly to movement of helix 7. In contrast to the model presented here, other published models were built using ideal helical structures or following the sense of the bacteriorhodopsin structure rather than the actual available coordinates. The presented model for the dopamine G protein-coupled receptor can be reconciled with the recent rhodopsin projection structure (Schertler, G. F. X.; Villa, C.; Henderson, R. Projection Structure of Rhodopsin.

[1]  C. Strader,et al.  Identification and sequence of a binding site peptide of the beta 2-adrenergic receptor. , 1988, Biochemistry.

[2]  B. Roth,et al.  A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. , 1993, Molecular pharmacology.

[3]  K. Neve,et al.  Regulation of dopamine D2 receptors by sodium and pH. , 1991, Molecular pharmacology.

[4]  J. Thornton,et al.  Influence of proline residues on protein conformation. , 1991, Journal of molecular biology.

[5]  H. Khorana,et al.  Mapping of the amino acids in membrane-embedded helices that interact with the retinal chromophore in bovine rhodopsin. , 1991, The Journal of biological chemistry.

[6]  J Hoflack,et al.  Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.

[7]  D. Grandy,et al.  Cloning of the cDNA and gene for a human D2 dopamine receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Venter,et al.  Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. , 1989, Molecular pharmacology.

[9]  Brian K. Kobilka,et al.  Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin , 1986, Nature.

[10]  S. Vishveshwara,et al.  Characterization of proline‐containing α‐helix (helix F model of bacteriorhodopsin) by molecular dynamics studies , 1993, Proteins.

[11]  J. Wess Molecular basis of muscarinic acetylcholine receptor function. , 1993, Trends in pharmacological sciences.

[12]  E. Atkinson,et al.  Emetic activity of N-substituted norapomorphines. , 1975, Journal of medicinal chemistry.

[13]  P. Seeman Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[14]  J Hoflack,et al.  Re-evaluation of bacteriorhodopsin as a model for G protein-coupled receptors. , 1994, Trends in pharmacological sciences.

[15]  J. Nathans,et al.  Isolation and nucleotide sequence of the gene encoding human rhodopsin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Ovchinnikov YuA Rhodopsin and bacteriorhodopsin: structure-function relationships. , 1982, FEBS letters.

[17]  H Weinstein,et al.  Signal transduction by a 5-HT2 receptor: a mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. , 1993, Journal of medicinal chemistry.

[18]  V. Cody,et al.  Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. , 1993, Journal of medicinal chemistry.

[19]  T. Gallaher,et al.  Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. , 1993, Molecular pharmacology.

[20]  M. Whitlow,et al.  An empirical examination of potential energy minimization using the well-determined structure of the protein crambin , 1986 .

[21]  C. Strader,et al.  Identification of residues required for ligand binding to the beta-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J Hoflack,et al.  Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.

[23]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[24]  J. Sack,et al.  CHAIN — A crystallographic modeling program , 1988 .

[25]  R. Williamson,et al.  Evidence for the Importance of a Carboxyl Group in the Binding of Ligands to the D2 Dopamine Receptor , 1990, Journal of neurochemistry.

[26]  M. Whitlow,et al.  Energy minimization for tertiary structure prediction of homologous proteins: alpha 1-purothionin and viscotoxin A3 models from crambin. , 1985, Journal of biomolecular structure & dynamics.

[27]  P. Seeman,et al.  Dopamine D1 receptor mutagenesis: role of amino acids in agonist and antagonist binding. , 1993, Biochemical and biophysical research communications.

[28]  R. Baldessarini,et al.  Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain. , 1990, Journal of medicinal chemistry.

[29]  R. Dixon,et al.  cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Summers,et al.  Adrenoceptors and Their Second Messenger Systems , 1993, Journal of neurochemistry.

[31]  K. Bogeso,et al.  Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition. , 1988, Journal of medicinal chemistry.

[32]  N. Pollock,et al.  Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. , 1992, The Journal of biological chemistry.

[33]  E. Eliopoulos,et al.  Three-dimensional modelling of G protein-linked receptors. , 1990, Trends in pharmacological sciences.

[34]  C. Branden,et al.  Introduction to protein structure , 1991 .

[35]  R. Deth,et al.  Precoupling of Gi/G(o)-linked receptors and its allosteric regulation by monovalent cations. , 1993, Life sciences.

[36]  B. Kobilka,et al.  Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. , 1992, Molecular pharmacology.

[37]  M. Caron,et al.  Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. , 1992, The Journal of biological chemistry.

[38]  R Henderson,et al.  The structure of bacteriorhodopsin and its relevance to the visual opsins and other seven-helix G-protein coupled receptors. , 1990, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[39]  C. D. Livingstone,et al.  Molecular modelling of D2-like dopamine receptors. , 1992, The Biochemical journal.

[40]  Jones Ta,et al.  Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. , 1985, Methods in enzymology.

[41]  J. Wess Molecular basis of muscarinic receptor function , 1993 .

[42]  J. Baldwin The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[43]  K. Neve,et al.  Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. , 1991, Molecular pharmacology.

[44]  P. Seeman,et al.  The conformation of dopamine at its receptor: binding of monohydroxy-2-aminotetralin enantiomers and positional isomers. , 1979, Molecular Pharmacology.

[45]  Gebhard F. X. Schertler,et al.  Projection structure of rhodopsin , 1993, Nature.

[46]  M. Caron,et al.  Role of extracellular disulfide-bonded cysteines in the ligand binding function of the beta 2-adrenergic receptor. , 1990, Biochemistry.

[47]  B. Kobilka,et al.  Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. , 1993, Molecular pharmacology.

[48]  R. Henderson The structure of bacteriorhodopsin and its relevance to other membrane proteins. , 1979, Society of General Physiologists series.

[49]  D. Grandy,et al.  Cloning and expression of a rat D2 dopamine receptor cDNA , 1988, Nature.

[50]  H. Khorana,et al.  Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[51]  C. Fraser,et al.  Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. , 1991, Molecular pharmacology.

[52]  P. Seeman,et al.  Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  E. Hulme,et al.  Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. , 1990, The Journal of biological chemistry.

[54]  B. O'dowd,et al.  A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.

[55]  P. Seeman,et al.  Regulation of Anterior Pituitary D2 Dopamine Receptors by Magnesium and Sodium Ions , 1985, Journal of neurochemistry.

[56]  J. Shine,et al.  Protein-coupled Receptors , 1996 .

[57]  R. Baldessarini,et al.  A stereochemical and conformational model of dopaminergic agonist and antagonist activity: further evaluation. , 1987, Journal of pharmaceutical sciences.

[58]  L. Birnbaumer,et al.  G proteins in signal transduction. , 1990, Annual review of pharmacology and toxicology.

[59]  R. Henderson,et al.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.

[60]  M. Froimowitz,et al.  Conformational properties of semirigid antipsychotic drugs: the pharmacophore for dopamine D-2 antagonist activity. , 1991, Journal of medicinal chemistry.

[61]  P. Stolk [Antipsychotic agents]. , 1988, Nederlands tijdschrift voor geneeskunde.

[62]  A. Kerlavage,et al.  Molecular biology of adrenergic and muscarinic cholinergic receptors. A perspective. , 1989, Biochemical pharmacology.

[63]  J. Ponder,et al.  Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. , 1987, Journal of molecular biology.

[64]  P. Strange New insights into dopamine receptors in the central nervous system , 1993, Neurochemistry International.

[65]  I. Sylte,et al.  Molecular dynamics of dopamine at the D2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Seeman,et al.  The Dopamine/Neuroleptic Receptor , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[67]  S. Hjorth,et al.  Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. , 1985, Journal of Medicinal Chemistry.

[68]  W. C. Probst,et al.  Sequence alignment of the G-protein coupled receptor superfamily. , 1992, DNA and cell biology.

[69]  S. Roe,et al.  Atomic resolution (0.83 A) crystal structure of the hydrophobic protein crambin at 130 K. , 1993, Journal of molecular biology.

[70]  H. Kao,et al.  Site‐directed mutagenesis of a single residue changes the binding properties of the serotonin 5‐HT2 receptor from a human to a rat pharmacology , 1992, FEBS letters.

[71]  P B Sigler,et al.  The 2.2 A crystal structure of transducin-alpha complexed with GTP gamma S. , 1994, Nature.

[72]  K Konvicka,et al.  A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.

[73]  B. Largent,et al.  N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors. , 1987, Journal of medicinal chemistry.

[74]  P. Chanda,et al.  Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. , 1993, Molecular pharmacology.

[75]  H. Akil,et al.  Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.

[76]  B. Sommer,et al.  The dopamine D2 receptor: two molecular forms generated by alternative splicing. , 1989, The EMBO journal.

[77]  C. Strader,et al.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.

[78]  C. Fraser Site-directed mutagenesis of beta-adrenergic receptors. Identification of conserved cysteine residues that independently affect ligand binding and receptor activation. , 1989, The Journal of biological chemistry.

[79]  C. Strader,et al.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.

[80]  P. Seeman,et al.  Cloning of two additional catecholamine receptors from rat brain , 1990, FEBS letters.